2-(4-Ethylbenzyl)aniline | 841236-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Ethylbenzyl)aniline
• 英文别名: 2-[(4-ethylphenyl)methyl]aniline
• CAS: 841236-85-9
• 化学式: C₁₅H₁₇N
• 分子量: 211.307
• InChiKey: FODKJHAEYSDVMY-UHFFFAOYSA-N

物化性质

• 沸点：
  352.6±11.0 °C(Predicted)
• 密度：
  1.036±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  glucose 、 2-(4-Ethylbenzyl)aniline 在 氯化铵 作用下， 以 甲醇 为溶剂， 以56%的产率得到2-(4-ethylbenzyl)-N-(beta-D-glucopyranosyl)aniline
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042
• 作为产物：
  描述：

  邻硝基苯甲醛 在 三乙基硅烷 、 正丁基锂 、 palladium on activated charcoal 、 三氟化硼乙醚 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 乙腈 为溶剂， 生成 2-(4-Ethylbenzyl)aniline
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042

文献信息

• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20070060545A1

  公开（公告）日：2007-03-15

  A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH 2 — group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B分别为（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，或（3）环A为可选取代的不饱和融合杂双环，其中—NR—基团和—CH2—基团均位于不饱和融合杂双环的同一环上，环B为可选取代的单环不饱和杂环、可选取代的不饱和融合杂双环或可选取代的苯环；R为氢原子、低碳基、低烷酰基或低烷氧羰基基团，或其药学上可接受的盐或前药。
• N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07521430B2

  公开（公告）日：2009-04-21

  A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式：其中环A和环B是(1) 环A是可选取代的不饱和单环杂环环，环B是可选取代的不饱和单环杂环环、可选取代的不饱和融合杂双环环或可选取代的苯环，(2) 环A是可选取代的苯环，环B是可选取代的不饱和单环杂环环、可选取代的不饱和融合杂双环环或可选取代的苯环，或(3) 环A是可选取代的不饱和融合杂双环环，其中—NR—基团和—CH2—基团都在不饱和融合杂双环环的同一环上，环B是可选取代的单环不饱和杂环环、可选取代的不饱和融合杂双环环或可选取代的苯环；R是氢原子、低烷基、低烷酰基或低烷氧羰基基团，或其药学上可接受的盐，或其前药。
• NOVEL COMPOUNDS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1654269B1

  公开（公告）日：2014-10-15
• US7521430B2
  申请人：——

  公开号：US7521430B2

  公开（公告）日：2009-04-21
• N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors
  作者：Yasuo Yamamoto、Eiji Kawanishi、Yuichi Koga、Shigeki Sakamaki、Toshiaki Sakamoto、Kiichiro Ueta、Yasuaki Matsushita、Chiaki Kuriyama、Minoru Tsuda-Tsukimoto、Sumihiro Nomura

  DOI：10.1016/j.bmcl.2013.08.042

  日期：2013.10

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.